{"filing":{"accession_number":"0001104659-26-077506","cik":"0001612940","ticker":"PRQR","company_name":"ProQR Therapeutics N.V.","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"tm2618527d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612940/000110465926077506/tm2618527d1_6k.htm"},"events":[{"id":13676,"run_id":12145,"accession_number":"0001104659-26-077506","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces positive Phase 1 clinical trial data for AX-0810, ProQR's first Axiomer RNA editing oligonucleotide, demonstrating dose-dependent target engagement on NTCP biomarkers in healthy volunteers with a favorable safety profile. The announcement represents a material clinical milestone validating the company's proprietary RNA editing platform technology and supporting advancement to next-generation candidates and Phase 2 development, which would affect a reasonable investor's assessment of the company's pipeline progress and technology viability.","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":10887,"accession_number":"0001104659-26-077506","item_number":"EX-99.1","item_title":"tm2618527d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive Phase 1 clinical trial data for AX-0810, ProQR's first Axiomer RNA editing oligonucleotide, demonstrating dose-dependent target engagement on NTCP biomarkers in healthy volunteers with a favorable safety profile. The announcement represents a material clinical milestone validating the company's proprietary RNA editing platform technology and supporting advancement to next-generation candidates and Phase 2 development, which would affect a reasonable investor's assessment of the company's pipeline progress and technology viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:31:53.436247+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10887,"accession_number":"0001104659-26-077506","item_number":"EX-99.1","item_title":"tm2618527d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive Phase 1 clinical trial data for AX-0810, ProQR's first Axiomer RNA editing oligonucleotide, demonstrating dose-dependent target engagement on NTCP biomarkers in healthy volunteers with a favorable safety profile. The announcement represents a material clinical milestone validating the company's proprietary RNA editing platform technology and supporting advancement to next-generation candidates and Phase 2 development, which would affect a reasonable investor's assessment of the company's pipeline progress and technology viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:31:53.436247+00:00","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-06-25"}]}